OBIO
Orchestra BioMed Holdings, Inc.
NASDAQ · Healthcare · Biotechnology · US
$5.08
+7.17%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 32.0M | 33.5M | 2.6M | 2.8M | 3.5M |
| Cost of Revenue | 217.0K | 190.0K | 204.0K | 186.0K | 322.0K |
| Gross Profit | 31.8M | 33.3M | 2.4M | 2.6M | 3.2M |
| Operating Expenses | |||||
| R&D Expense | 63.2M | 58.2M | 42.8M | 33.8M | 21.9M |
| SG&A Expense | 26.6M | 26.9M | 23.9M | 20.3M | 13.9M |
| General & Admin Expense | 5.8M | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | (30.0K) | — | — | — | — |
| Total Operating Expenses | 89.8M | 85.1M | 66.7M | 54.1M | 35.9M |
| Cost and Expenses | 90.0M | 85.3M | 66.9M | 54.3M | 36.2M |
| Operating Income (EBIT) | (58.0M) | (51.8M) | (64.3M) | (51.5M) | (32.7M) |
| Non-Operating | |||||
| Interest Income | — | — | 3.4M | 3.8M | 50.0K |
| Interest Expense | 2.1M | 1.1M | — | — | — |
| Net Interest Income | (2.1M) | (1.1M) | 3.4M | 3.8M | 50.0K |
| Other Non-Op Income/Expense | (1.0M) | (894.0K) | 3.3M | 2.4M | (951.0K) |
| Non-Operating Income (excl Interest) | (546.0K) | (254.0K) | (3.3M) | (2.4M) | 951.0K |
| EBT (Pre-Tax Income) | (59.0M) | (52.7M) | (61.0M) | (49.1M) | (33.6M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (59.0M) | (52.7M) | (61.0M) | (49.1M) | (33.6M) |
| Earnings from Cont. Ops | (59.0M) | (52.7M) | (61.0M) | (49.1M) | (33.6M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (59.6M) | (53.0M) | (61.0M) | (49.1M) | (33.6M) |
| Per Share | |||||
| Basic EPS | ($0.99) | ($1.11) | ($1.66) | ($1.48) | ($1.32) |
| Diluted EPS | ($0.99) | ($1.11) | ($1.66) | ($1.48) | ($1.32) |
| Revenue Per Share | $0.50 | $0.70 | $0.07 | $0.08 | $0.14 |
| Shares | |||||
| Basic Shares Outstanding | 63.8M | 47.7M | 36.8M | 33.2M | 25.5M |
| Diluted Shares Outstanding | 63.8M | 47.7M | 36.8M | 33.2M | 25.5M |
| Profitability Metrics | |||||
| EBITDA | (57.1M) | (51.2M) | (60.7M) | (48.8M) | (33.4M) |
| D&A | 349.0K | 327.0K | 308.0K | 287.0K | 222.0K |
| EBIT | (57.4M) | (51.6M) | (61.0M) | (49.1M) | (33.6M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026